149 related articles for article (PubMed ID: 38289075)
1. Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19.
Yang H; Yu X; Hou W; Liu X; Chen J; Zhang Y; Wang Y; Zhu Y; Qian Q; Ma K; An Z
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0138423. PubMed ID: 38289075
[TBL] [Abstract][Full Text] [Related]
2. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment.
Toussi SS; Neutel JM; Navarro J; Preston RA; Shi H; Kavetska O; LaBadie RR; Binks M; Chan PLS; Demers N; Corrigan B; Damle B
Clin Pharmacol Ther; 2022 Oct; 112(4):892-900. PubMed ID: 35712797
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies.
Tang Y; Li Y; Song T
Front Immunol; 2023; 14():1150341. PubMed ID: 37081880
[TBL] [Abstract][Full Text] [Related]
5. Early Experience with Modified Dose Nirmatrelvir/Ritonavir in Dialysis Patients with Coronavirus Disease 2019.
Hiremath S; Blake PG; Yeung A; McGuinty M; Thomas D; Ip J; Brown PA; Pandes M; Burke A; Sohail QZ; To K; Blackwell L; Oliver M; Jain AK; Chagla Z; Cooper R
Clin J Am Soc Nephrol; 2023 Apr; 18(4):485-490. PubMed ID: 36723285
[TBL] [Abstract][Full Text] [Related]
6. Nirmatrelvir/ritonavir-induced elevation of blood tacrolimus levels in a patient in the maintenance phase post liver transplantation.
Shiohira H; Arakaki S; Uehara W; Uehara H; Yamamoto K; Nakamura K
J Infect Chemother; 2024 Jan; 30(1):77-80. PubMed ID: 37689137
[TBL] [Abstract][Full Text] [Related]
7. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019.
Chan GCK; Lui GCY; Wong CNS; Yip SST; Li TCM; Cheung CSK; Sze RKH; Szeto CC; Chow KM
Clin Infect Dis; 2023 Nov; 77(10):1406-1412. PubMed ID: 37531093
[TBL] [Abstract][Full Text] [Related]
8. Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study.
Chu WM; Wan EYF; Ting Wong ZC; Tam AR; Kei Wong IC; Yin Chan EW; Ngai Hung IF
EClinicalMedicine; 2024 Jun; 72():102620. PubMed ID: 38737003
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
[TBL] [Abstract][Full Text] [Related]
10. Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series.
Guzmán Cordero C; Saez-Torres de Vicente M
Eur J Hosp Pharm; 2024 Feb; 31(2):175-177. PubMed ID: 36535689
[TBL] [Abstract][Full Text] [Related]
11. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients.
Salerno DM; Jennings DL; Lange NW; Kovac DB; Shertel T; Chen JK; Hedvat J; Scheffert J; Brown RS; Pereira MR
Am J Transplant; 2022 Aug; 22(8):2083-2088. PubMed ID: 35278260
[TBL] [Abstract][Full Text] [Related]
12. The effects of nirmatrelvir/ritonavir on tacrolimus levels in lung transplant recipients: A single-center study.
Wang X; Du W; Zhang D; Chen W; Zuo X
Pulm Pharmacol Ther; 2024 Mar; 84():102280. PubMed ID: 38065402
[TBL] [Abstract][Full Text] [Related]
13. Nirmatrelvir/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series.
Dewey KW; Yen B; Lazo J; Seijo L; Jariwala R; Shah RJ; Quan D; Carpenter B; Paul Singer J; Breen K; Hays S; Florez R
Transplantation; 2023 May; 107(5):1200-1205. PubMed ID: 36525555
[TBL] [Abstract][Full Text] [Related]
14. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".
Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D
Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419
[TBL] [Abstract][Full Text] [Related]
15. Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion.
Marsh J; Logan AT; Bilgili EP; Bowman LJ; Webb AR
Am J Health Syst Pharm; 2024 Jun; 81(13):e345-e352. PubMed ID: 38347740
[TBL] [Abstract][Full Text] [Related]
16. A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19.
Tomida T; Itohara K; Yamamoto K; Kimura T; Fujita K; Uda A; Kitahiro Y; Yokoyama N; Hyodo Y; Omura T; Yano I
Drug Metab Pharmacokinet; 2023 Dec; 53():100529. PubMed ID: 37924724
[TBL] [Abstract][Full Text] [Related]
17. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
Transpl Int; 2024; 37():12360. PubMed ID: 38596505
[TBL] [Abstract][Full Text] [Related]
18. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
[TBL] [Abstract][Full Text] [Related]
19. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
20. A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient.
Lo CM; Chen WH; Tsai MY; Lu HI; Hsiao YH; Chuang KH; Chen Y; Wu HF; Huang KT; Wang YH
J Cardiothorac Surg; 2024 Mar; 19(1):132. PubMed ID: 38491538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]